Table 1. Baseline characteristics of the hemodialysis cohort by quartile of d-ROMs.
| No. of participants with data | d-ROMs quartile |
||||||
|---|---|---|---|---|---|---|---|
| Overall, N = 517 |
Q1 N = 130 |
Q2 N = 129 |
Q3 N = 129 |
Q4 N = 129 |
P values across quartiles |
||
| d-ROMs | 517 | 294 (250–350) | 220 (186–236) | 275 (263–284) | 318 (308–331) | 385 (366–419) | < 0.001 |
| Age (years) | 517 | 61 (54–68) | 56 (49–65) | 60 (54–65) | 62 (56–70) | 64 (59–69) | < 0.001 |
| Sex (%male) | 517 | 62.9 | 73.1 | 67.4 | 57.4 | 53.5 | 0.004 |
| Dialysis duration (month) | 517 | 114 (47–194) | 92 (35–171) | 116 (47–194) | 123 (53–202) | 131 (68–201) | 0.03 |
| Diabetic nephropathy (%) | 517 | 21.3 | 26.2 | 19.4 | 17.8 | 21.7 | 0.4 |
| Pre-existing CVD (%) | 517 | 33.5 | 30.8 | 29.5 | 29.5 | 44.2 | 0.03 |
| Systolic BP (mmHg) | 517 | 154 (141–164) | 153 (141–164) | 155 (142–166) | 153 (143–163) | 151 (134–163) | 0.2 |
| Diastolic BP (mmHg) | 517 | 79 (74–82) | 79 (74–84) | 79 (74–83) | 78 (73–82) | 77 (72–81) | 0.01 |
| RASi use (%) | 517 | 36.0 | 48.5 | 34.1 | 34.1 | 27.1 | 0.004 |
| Non-RASi use(%) | 517 | 64.4 | 66.9 | 73.6 | 61.2 | 55.8 | 0.002 |
| Hypertension (%) | 517 | 86.3 | 90.0 | 89.1 | 88.4 | 77.5 | 0.01 |
| Smoker (%) | 517 | 41.0 | 36.2 | 42.6 | 43.4 | 41.9 | 0.6 |
| HDL-C (mg/dL) | 517 | 44.2 (36–54.2) | 43 (36–54) | 45 (37–58) | 45 (37.4–54.2) | 44 (36–52) | 0.6 |
| Non-HDL-C (mg/dL) | 517 | 115 (91–138) | 103 (88–135) | 110 (87–137) | 119 (95–146) | 120 (98–137) | 0.07 |
| Statin use (%) | 517 | 4.8 | 7.7 | 3.9 | 5.4 | 2.3 | 0.2 |
| BMI (kg/m2) | 517 | 21.5 (19.6–23.4) | 21.9 (19.9–23.2) | 21.8 (19.6–24.1) | 21.5 (19.5–23.4) | 21.5 (19.3–23.3) | 0.7 |
| Serum albumin (g/dL) | 517 | 3.7 (3.5–3.9) | 3.8 (3.6–4) | 3.7 (3.6–4) | 3.8 (3.6–3.9) | 3.6 (3.4–3.8) | < 0.001 |
| CRP (mg/dL) | 517 | 0.14 (0.05–0.41) | 0.05 (0.03–0.12) | 0.09 (0.05–0.2) | 0.15 (0.06–0.33) | 0.45 (0.19–1.25) | < 0.001 |
| Calcium (mg/dL) | 517 | 9.1 (8.6–9.8) | 9.1 (8.7–9.7) | 9.2 (8.8–9.9) | 9.1 (8.3–9.9) | 9.1 (8.4–9.7) | 0.2 |
| Phosphate (mg/dL) | 517 | 5.8 (5.0–6.6) | 5.6 (5–6.4) | 6 (5.4–6.7) | 5.8 (4.9–6.6) | 5.6 (4.7–6.6) | 0.02 |
| Intact PTH (pg/mL) | 517 | 118 (41–215) | 109 (43–214) | 130 (52–235) | 127 (44–201) | 97 (30–211) | 0.5 |
| VDRA use (%) | 517 | 44.3 | 46.2 | 39.5 | 48.1 | 43.4 | 0.5 |
| Hematocrit (%) | 517 | 30.7 (28.6–32.4) | 30.7 (29.2–32.2) | 31.4 (29.8–32.9) | 30.8 (28.5–32.4) | 29.1 (27–31.6) | < 0.001 |
| ESA dose (x1000 units/week) | 517 | 9.0 (7.5–9.0) | 9.0 (7.5–9.0) | 9.0 (7.5–9.0) | 9.0 (7.5–9.0) | 9.0 (7.5–9.0) | 0.8 |
| IV iron use (%) | 517 | 58.2 | 51.5 | 47.3 | 66.7 | 67.4 | 0.001 |
The table gives median (interquartile range) for continuous variables and percentages for categorical variables.
Abbreviations: d-ROMs, derivatives of reactive oxygen metabolites; Q, quartile; CVD, cardiovascular disease; BP, blood pressure; RASi, reninangiotensin system inhibitors; Non-RASi, antihypertensive medications other than RAS inhibitors; HDL, high-density lipoprotein; BMI, body mass index; CRP, C-reactive protein; PTH, parathyroid hormone; VDRA, vitamin D receptor activator; ESA, erythropoiesis stimulating agent; IV-iron, intravenous iron preparation.
Conversion factors for units: HDL-C and Non-HDL-C in mg/dL to mmol/L, × 0.02586; phosphorus in mg/dL to mmol/L, × 0.3229.